Pancreatic ductal adenocarcinoma (PDAC) frequently co-occurs with metabolic disorders such as obesity, diabetes, and cancer-associated cachexia. The pancreatic anabolic hormone insulin is implicated in these conditions, but its role in coordinating tumor growth with systemic host physiology has been unclear. This preclinical study used an orthotopic transplantation approach with patient-derived PDAC organoids to investigate how endogenous insulin levels influence tumor progression and host metabolic responses.
The investigators transplanted orthotopic PDAC patient-derived organoids into mice. To manipulate systemic insulin states, mice were fed a high-fat diet (HFD) that induces hyperinsulinemia or normal chow. The design allowed comparison of tumor and host metabolic outcomes under diet-driven hyperinsulinemia versus baseline dietary conditions. The source abstract does not report full methodological details such as sample sizes, specific genetic manipulations, timing, or statistical methods.
A key observation reported was that insulin concentrations measured within tumors were higher than circulating insulin levels. This finding suggests either local insulin accumulation in the tumor microenvironment or altered insulin handling by tumors. The abstract does not specify whether intratumoral insulin derives from local production, uptake from circulation, or both.
The authors reduced endogenous insulin genetically and assessed PDAC growth. Genetically lowering insulin levels diminished tumor growth overall, with the most notable reduction observed in mature male mice fed a high-fat diet. The abstract does not detail the specific genetic strategy used to reduce insulin, nor does it provide quantitative measures of tumor size reduction or duration of effect.
Reciprocal effects of tumor presence on host metabolism were observed. Pancreatic tumors increased systemic glucose clearance, indicating altered whole-body glucose handling in tumor-bearing mice. Additionally, presence of tumors limited the expected HFD-induced rises in circulating insulin, body weight, and fat mass. These changes demonstrate that tumors can feedback on and reshape the host’s metabolic response to diet.
Diet context modified the metabolic interplay between tumor and host. In HFD-fed mice, genetically lowering insulin had a pronounced anti-tumor effect in mature males, and tumors attenuated diet-driven gains in insulin, weight, and fat mass. By contrast, in mice fed normal chow, tumor growth was associated with declining circulating insulin as well as loss of fat and muscle mass—features consistent with cancer-associated wasting. Thus, tumor–host metabolic dynamics differed by dietary state, linking PDAC, insulin, and body composition changes through distinct patterns depending on nutrient environment.
Collectively, these data provide new preclinical evidence for a dynamic, insulin-centered coordination between PDAC and systemic metabolism. The findings indicate that endogenous insulin supports tumor growth under certain metabolic conditions while tumors reciprocally alter host glucose handling and body composition. These interactions may underlie components of cancer-associated metabolic dysfunction such as impaired glucose homeostasis and tissue wasting.
Limitations based on the source abstract: the report does not include detailed methods, quantitative results, timelines, or sample size information. It also does not specify the mechanism by which tumors concentrate insulin or the exact genetic approach used to reduce insulin. Those details would be necessary to assess translational implications and to design follow-up studies.
The authors report a competing interest: Christoph H. Borchers is Scientific Advisor of MRM Proteomics Inc. and Vice President of Proteomics at Molecular You. The work is posted as a bioRxiv preprint (posted August 27, 2026) under a CC-BY-NC-ND 4.0 license. No further conflicts or external validations are reported in the abstract.